Breaking Convention puts the psychedelic back into psychedelic conferences
Journey to the druidic lands of Exeter for a gathering of science and spirituality. Join me in revisiting Breaking Convention 2023.
Blossom’s Bits
Psychedelics in the European Parliament
PAREA organised a meeting in the European Parliament on psychedelic-assisted therapies for the treatment of mental health issues.
The Severe Lack of Long-Term Psychedelic Studies
212 people that have gone through psychedelic trials for which we have data that extends beyond 3 months. We need more data if we want psychedelic-assisted therapy (PAT) to scale.
Lessons from the Interdisciplinary Conference on Psychedelic Research 2022
The take home messages from the Interdisciplinary Conference on Psychedelic Research 2022. Novel results, DMT, and a personal note.
At-home ketamine is safe and effective?
Researchers associated with Mindbloom just published an article arguing that at-home ketamine-assisted therapy is not only safe but led to improvements (<50%) in depression and anxiety in 62% of participants.
Who is going to benefit from psychedelic therapy?
Psychedelic therapy is going mainstream – it won’t be long before these therapies are rolled out in clinics across the globe once the regulations around these substances are changed.
It’s time to build psychedelic infrastructure
Health systems are unprepared to offer and meet the demand for psychedelic-assisted therapy – we can start to prepare now.
Is funding for psychedelic research changing?
The legal issues and stigma surrounding psychedelics have deterred many traditional sources from funding – now, things are changing.
The next generation of psychedelics
The next generation of psychedelics is already here – let’s take a look at the advantages and disadvantages.
The Size of the Psychedelic Market
Despite psychedelics remaining highly controlled – it hasn’t deterred investors and a sizeable market has developed.